Similar articles for PMID: 35641262

Year	Number of Results
2000	1
2003	2
2004	1
2008	1
2009	2
2012	1
2013	1
2014	5
2015	6
2016	6
2017	1
2018	8
2019	15
2020	24
2021	30
2022	19
2023	6
2024	0

1

The Outcome of Conversion Liver Resection Surgery by Lenvatinib Treatment: A Single Center Experience.

Hidaka M, Hara T, Soyama A, Sasaki R, Matsushima H, Tanaka T, Hamada T, Imamura H, Adachi T, Kanetaka K, Miyaaki H, Okano S, Eguchi S. Hidaka M, et al. Anticancer Res. 2022 Jun;42(6):3049-3054. doi: 10.21873/anticanres.15791. Anticancer Res. 2022. PMID: 35641262

2

Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.

Kunimoto H, Shakado S, Tanaka T, Takata K, Yamauchi R, Fukuda H, Tsuchiya N, Yokoyama K, Morihara D, Takeyama Y, Hirai F, Sakisaka S. Kunimoto H, et al. Oncology. 2020;98(11):779-786. doi: 10.1159/000509005. Epub 2020 Sep 2. Oncology. 2020. PMID: 32877911

3

A Multidisciplinary Treatment Strategy With Conversion Surgery for Hepatocellular Carcinoma.

Shiozaki H, Furukawa K, Haruki K, Matsumoto M, Uwagawa T, Onda S, Yamahata Y, Ishizaki S, Abe K, Fujioka S, Nakaseko Y, Okamoto T, Ikegami T. Shiozaki H, et al. Anticancer Res. 2023 Apr;43(4):1761-1766. doi: 10.21873/anticanres.16329. Anticancer Res. 2023. PMID: 36974796

4

A case of conversion hepatectomy for huge ruptured hepatocellular carcinoma after transarterial embolization and lenvatinib therapy.

Naganuma A, Suzuki Y, Hoshino T, Yasuoka H, Tamura Y, Naruse H, Tanaka H, Hirai K, Sakamoto I, Ogawa T, Hatanaka T, Kakizaki S. Naganuma A, et al. Clin J Gastroenterol. 2022 Feb;15(1):177-184. doi: 10.1007/s12328-021-01558-5. Epub 2021 Nov 22. Clin J Gastroenterol. 2022. PMID: 34811701

5

Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.

Kirino S, Tsuchiya K, Kurosaki M, Kaneko S, Inada K, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Okada M, Wang W, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Izumi N. Kirino S, et al. PLoS One. 2020 Apr 20;15(4):e0231828. doi: 10.1371/journal.pone.0231828. eCollection 2020. PLoS One. 2020. PMID: 32310967 Free PMC article.

6

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.

Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, Okusaka T, Tamai T, Suzuki T, Hisai T, Hayato S, Okita K, Kumada H. Ikeda K, et al. J Gastroenterol. 2017 Apr;52(4):512-519. doi: 10.1007/s00535-016-1263-4. Epub 2016 Oct 4. J Gastroenterol. 2017. PMID: 27704266 Free PMC article. Clinical Trial.

7

Prognostic Impact of Surgical Intervention After Lenvatinib Treatment for Advanced Hepatocellular Carcinoma.

Shindoh J, Kawamura Y, Kobayashi Y, Kobayashi M, Akuta N, Okubo S, Suzuki Y, Hashimoto M. Shindoh J, et al. Ann Surg Oncol. 2021 Nov;28(12):7663-7672. doi: 10.1245/s10434-021-09974-0. Epub 2021 Apr 26. Ann Surg Oncol. 2021. PMID: 33904001

8

Conversion Hepatectomy for Huge Hepatocellular Carcinoma With Arterioportal Shunt After Chemoembolization and Lenvatinib Therapy.

Sato N, Beppu T, Kinoshita K, Yuki H, Suyama K, Chiyonaga S, Motohara T, Komohara Y, Hara A, Akahoshi S. Sato N, et al. Anticancer Res. 2019 Oct;39(10):5695-5701. doi: 10.21873/anticanres.13768. Anticancer Res. 2019. PMID: 31570469

9

The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy.

Yoshimoto T, Imura S, Morine Y, Ikemoto T, Arakawa Y, Iwahashi S, Saito YU, Takasu C, Ishikawa D, Teraoku H, Bando Y, Shimada M. Yoshimoto T, et al. Anticancer Res. 2018 Jan;38(1):501-507. doi: 10.21873/anticanres.12250. Anticancer Res. 2018. PMID: 29277815

10

Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment.

Yamashige D, Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Okubo S, Muraishi N, Kajiwara A, Iritani S, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kumada H. Yamashige D, et al. Oncology. 2021;99(3):169-176. doi: 10.1159/000510754. Epub 2020 Nov 18. Oncology. 2021. PMID: 33207358 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

113 results

Results by year